✨ Free AI Report
Kiniksa Pharmaceuticals International, plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Kiniksa Pharmaceuticals International, plc
Company Research

Kiniksa Pharmaceuticals International, plc: Business Overview, Financials & Competitive Analysis

Kiniksa Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. The company achieved full-year profitabil...

Analyst-debate audio for Kiniksa Pharmaceuticals International, plc

AskCyborg analysts argue the bull and bear cases for Kiniksa Pharmaceuticals International, plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
8/ 10Strong

Cyborg Score thesis

Revenue-profitability inflection story with strong cash generation and focused pipeline, but execution risks around single asset...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Specialty & Immunology
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Kiniksa Pharmaceuticals International, plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Kiniksa Pharmaceuticals International, plc Overview

Pro stress-test →

Kiniksa Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. The company achieved full-year profitability in 2025 propelled by exceptional commercial performance of its flagship drug, ARCALYST. ARCALYST generated 2025 net product revenue of $677.5 million, representing ~62% year-over-year growth.

Strategic Profile

Pro stress-test →

IL-1α & IL-1β inhibition with ARCALYST is increasingly becoming the preferred second line treatment for patients with recurrent pericarditis, with approximately 18% of the multiple recurrence population actively on ARCALYST therapy as of end-2025. The company has disciplined focus of R&D resources on its next-generation IL-1 inhibitor pipeline (KPL-387 and KPL-1161), following discontinuation of other clinical programs.

Competitive Landscape

Pro stress-test →

Kiniksa competes in the biopharmaceutical space focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Primary competitors include other cardiovascular specialty pharma companies and immunology-focused biotech firms pursuing IL-1 pathway interventions.

Industry Context

Kiniksa Pharmaceuticals International, plc operates in Biopharmaceuticals - Specialty & Immunology.

Key facts

Founded: 2015 · Headquarters: London, UK · Revenue: $678M · Market cap: $3.24B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Kiniksa Pharmaceuticals International, plc.

  • ARCALYST 2026 net product revenue expected to be $900 - $920 million, representing ~34% YoY growth guidance
  • Operating margin made dramatic swing from negative 10.8% in 2024 to positive 11.4% in 2025, underscoring scalability of commercial model
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Reported full-year 2025 results with $677.5M ARCALYST revenue (62% YoY growth) and achieved profitability
  • February 2026Issued 2026 ARCALYST revenue guidance of $900-$920M
  • +1 moreTrack every material event for Kiniksa Pharmaceuticals International, plc as it happens. Explore monitoring →
Get alerted when Kiniksa Pharmaceuticals International, plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

IL-1 Pathway InhibitorsVarious companies pursuing IL-1 inhibition for cardiovascular and inflammatory conditions→Cardiovascular Specialty PharmaCompetitors in rare cardiovascular disease treatment space→

Compare Kiniksa Pharmaceuticals International, plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Kiniksa Pharmaceuticals International, plc operates in Biopharmaceuticals - Specialty & Immunology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Specialty & Immunology research →
NEW · MCP server

Ask your AI assistant about Kiniksa Pharmaceuticals International, plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Kiniksa Pharmaceuticals International, plc and its top competitor on Cyborg Score”
“What did Kiniksa Pharmaceuticals International, plc do this quarter?”
“Is Kiniksa Pharmaceuticals International, plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Kiniksa Pharmaceuticals International, plc do?+
Kiniksa Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. The company achieved full-year profitabil...
What is Kiniksa Pharmaceuticals International, plc's Cyborg Score?+
Kiniksa Pharmaceuticals International, plc has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Kiniksa Pharmaceuticals International, plc's main competitors?+
Named competitors include IL-1 Pathway Inhibitors, Cardiovascular Specialty Pharma. The full competitive landscape is in the AskCyborg report.
How can I get the full Kiniksa Pharmaceuticals International, plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Kiniksa Pharmaceuticals International, plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Kiniksa Pharmaceuticals International, plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.